MTOR and prostate cancer: Interestingly, GDC-0980 treatment alone decreased AR levels and this effect could be enhanced further by the addition of CDX, suggesting that mTOR activity may contribute to elevated AR protein levels (Figure 5B), similar to the signaling observed in prostate cancer [13].